Radcon2017 Posted - 2 hours ago

$FBIO Daily Chart Heating Up for FBIO…3 Potential Price Targets For Consideration… Target #1 200 Day Average around $3.00 Target #2 Gap Area in $3.50 Zone Target #3 Resistance Zone around $5.00 Daily Charts for $XBI, $QQQ, $SPY looking bullish also… Good insider activity on both $FBIO and $DERM…FBIO has many positions in many biotechs with several catalysts…They own a large chunk of $DERM…I am Long FBIO… It appears this channel pattern pressure could be ventilated to the upside based on Friday’s close…This is my opinion and no guarantees…$FBIO looks compelling here…

Radcon2017 Posted - 3 hours ago

$FBIO All Systems Go as Price is showing a bullish hourly breakout higher…The 20 Hour, 50 Hour, and 200 Hour are Converging and beginning to crossover while sloping upwards which is bullish…I think our time may be coming as this multi month channel pattern looks to resolve itself…With Volume increasing into Friday, we may see a move higher…I am hopeful looking for bullish confirmation with a close above $2.25 in my opinion…Insiders hold a good position both here and in $DERM…$FBIO has been in a channel pattern for months and it appears that we may have witnessed Quiet Accumulation of $FBIO…Also $XBI, $QQQ, AND $SPY all looking bullish on the Daily… Do your Due Diligence and review FBIO posts…lots of opportunity here in my opinion…

DameWave Posted - 5 hours ago

$FBIO My belief is that they will be bought out a maximum of one month after the FDA confirms the new PDUFA. $CKPT

DameWave Posted - 6 hours ago

$FBIO Dotinurad data is days or weeks away to confirm what we already know from the 1000 patients in Japan. This is one of several drugs that can generate billions for FBIO ($36 M market cap). For more info on Urica read my series of posts from April 17 and yesterday and May 5 here on ST. $AMGN $XBI $IBB

DameWave Posted - 6 hours ago

$XBI $FBIO $DERM

DameWave Posted - 7 hours ago

$FBIO "Guidance definitely unchanged" with at least break even for $DERM 2024, in response from Q&A in Q1 (click on link below and listen to earnings webcast). The loss was due to: 1. One-time costs in the R&D segments (read earnings release or in the image below) which increased from $2.0 M to $7.9 M 2. Q1 is historically a weak quarter due to their best seller Qbrexza (topical treatment of primary axillary hyperhidrosis) of logical seasonal patterns selling significantly less in Q4-Q1 compared to Q2-Q3 (last comparable period the increase was 20.8%) https://event.choruscall.com/mediaframe/webcast.html?webcastid=UYHNGDtl

DameWave Posted - 19 hours ago

$XBI $FBIO

BioAmerica Posted - 1 day ago

$FBIO It is a shelf filing stupid. If you don't understand the filing, you don't need to be investing in stocks, much less posting about it. Try mutual fund.s

josegodoy Posted - 1 day ago

$FBIO got this on watch

DameWave Posted - 1 day ago

$FBIO Spreading the word about DFD-29 $DERM

DameWave Posted - 1 day ago

$FBIO No! So far you are wrong by as many millions... Take a breath and read the S-3 document again. If you don't understand then read specifically about "mixed securities shelf offering". Read especially the red text on page 2 and the text in the image below from the same image. https://www.fortressbiotech.com/investors/sec-filings/all-sec-filings/content/0001104659-24-063035/0001104659-24-063035.pdf

DonCorleone77 Posted - 1 day ago

$FBIO Fortress Biotech files $50M mixed securities shelf

justbaseball25 Posted - 1 day ago

$fbio huge offering of $50 mil

DameWave Posted - 1 day ago

$FBIO Now you can watch the $DERM presentation on Youtube Journey Medical Corporation (NASDAQ: DERM) Webcast | Planet MicroCap Showcase: VEGAS 2024 https://www.youtube.com/watch?v=cn9-aWLFL-o

SWICH Posted - 2 days ago

$FBIO they just filed a Form 144 to allow the sale of restricted shares of one of their subsidiaries. Anyone seen them do this before?

DameWave Posted - 2 days ago

$FBIO Milestones today - 25 24 Q2-Q4 Qbrexza & DFD-29 sales deal outside US 24 Q2: AJ201 Phase 1n/2a top-line data 24 Q2-Q3: Cosibelimab resubmission 24 Q2-Q3: Dotinurad Phase 1b data 24 Q2-Q4: AAV-ATP7A Gene Therapy nominate candidate for P1 24 Q2-Q4: MB-106 additional safety and efficacy data from Mustang-IND 24 Q2-Q4: MB-106 Phase 1 start for autoimmune diseases in Q4 24 24 Q2-Q4: IV Tramadol Initiate pivotal Phase 3 safety trial 24 Q2-Q4: CUTX-101 approval and priority review voucher worth ~$110 M 24 Q2-Q4: Triplex Phase 2 Kidney Transplant start 24 Q2-Q4: In vivo CAR-T murine tumor model data publication 24 Q4: DFD-29 approval 24 Q4 – 25 Q1: Cosibelimab approval 24-25: BAER101 Phase 2 start 24-25: Cosibelimab sales deals 24-25: Olafertinib Phase 3 update 24-25: Cosibelimab + Olafertinib Phase 1b start 25 H1: CAEL-101 data from 2 Phase 3 25: MB-109 (MB-101 + MB-108) Phase 1 data 25: Dotinurad pivotal trial start 25: CUTX-101 royalty sales 25 Q1: DFD-29 sales start 25 H2; CAEL-101 approval $XBI $IBB

DameWave Posted - 2 days ago

$FBIO Every institution that reported the figures for March and April has been a net buyer. https://www.morningstar.com/stocks/xnas/fbio/ownership

braves1983 Posted - 2 days ago

$FBIO lets get to $2

BioAmerica Posted - 2 days ago

@DameWave Every time I have a few hundred dollars left over after buying something else, I buy $FBIO. I've never seen a stock with such a large disconnect between the price and what it is worth. Hopefully, some day the markets will figure it out.

Radcon2017 Posted - 3 days ago

$FBIO personally I think at some point this company will hopefully be acquired…

omega42 Posted - 3 days ago

$FBIO $CKPT $ATXI $DERM Part of the issue why there is little interest in FBIO and related entities are constant offerings and RS to stay compliant as well as unwillingness to get in front of its investors other than occasional PR. looks like one way street.

braves1983 Posted - 3 days ago

$FBIO thanks for the wonderful earnings report. up 5% in afterhours and trading red during regular hours. same shit different day

justbaseball25 Posted - 3 days ago

Losing less money isn't making money $otrk $fbio

braves1983 Posted - 3 days ago

$FBIO and its red again

braves1983 Posted - 3 days ago

$FBIO it destroyed the earnings report and nothing happens. earnings reports are just traps for retailers

DonCorleone77 Posted - 3 days ago

$FBIO Fortress Biotech reports Q1 EPS ($1.03), consensus ($1.73) Reports Q1 revenue $13.03M, consensus $14.13M. Lindsay Rosenwald, Fortress' Chairman, President and Chief Executive Officer, said, "We achieved first quarter year-over-year product revenue growth of 7%, which was driven by greater than 20% year-over-year growth in our flagship products, Qbrexza(R) and Accutane(R). In the first quarter of 2024, the U.S. Food and Drug Administration ("FDA") accepted the New Drug Application ("NDA") filing for DFD-29 and set a Prescription Drug User Fee Act ("PDUFA") goal date of November 4, 2024. If approved, DFD-29 has the potential to be the only oral, systemic therapy to address inflammatory lesions and erythema (redness) from rosacea, differentiating it as a potential best-in-class solution for the millions of patients suffering from rosacea. We also dosed the first patient in a multi-center Phase 2 study for Triplex for control of cytomegalovirus ("CMV") in patients undergoing liver transplantation and received grant funding from the National Institutes of Health ("NIH") to further advance cell and gene therapy candidates for the potential treatment of adults living with HIV and children with Menkes disease. Looking ahead, our expansive portfolio of development-stage programs across multiple areas, including oncology, dermatology, and rare diseases, holds the potential for up to three NDA and Biologics License Application ("BLA") regulatory approvals within the next 12 months and potentially a fourth BLA filing as early as 2025. Additionally, we anticipate multiple data readouts this year, including topline data from the Phase 1b/2a clinical trial of AJ201 to treat spinal and bulbar muscular atrophy ("SBMA"), data from the Phase 1b clinical trial of dotinurad for the treatment of gout and hyperuricemia and topline Phase 2 clinical data of Triplex, a CMV vaccine for adults co-infected with HIV and CMV. This sustained progress underscores the strength of Fortress' business model, centered on acquiring and advancing assets that address unmet medical needs and enhance long-term value for shareholders through product revenues, equity holdings and royalties."

epsguid Posted - 3 days ago

$FBIO reported a loss of $1.03, consensus was ($2.03) via @eWhispers #epsbeat http://eps.sh/d/fbio

Stock_Titan Posted - 3 days ago

$FBIO Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights https://www.stocktitan.net/news/FBIO/fortress-biotech-reports-first-quarter-2024-financial-results-and-uw8ovbotl2gh.html

DameWave Posted - 3 days ago

$FBIO That $ARQT has a market cap of almost $1.1B and $DERM only $72 M is insane... DERM has 8 approved products and soon a blockbuster in DFD-29. ARQT has one approved product. DERM had $20 M more in sales than ARQT in 2023... Pure insanity! But it at least shows what DERM should be valued at at least in the near term. $XBI $IBB

DameWave Posted - 3 days ago

$FBIO Please read my series on $CKPT and their Cosibelimab, where the first part contains 28 parts/posts. Is finding a nano cap that has better data than the world's current best-selling drug by far as motivation enough? $XBI $IBB